Achaogen Inc., of South San Francisco, added Karen Bernstein to its board.

Achillion Pharmaceuticals Inc., of New Haven, Conn., named Mingjun Huang senior vice president and head of research.

Aeglea Biotherapeutics Inc., of Austin, Texas, appointed James Wooldridge chief medical officer.

Agex Therapeutics, a subsidiary of Biotime Inc., of Alameda, Calif., named Aubrey de Grey vice-president of new technology discovery.

Astellas Pharma Inc., of Tokyo, appointed David Musselman area vice president, sales, primary care and specialty – East, and Lynn Gerber area vice president, sales, primary care and specialty – West. They will be responsible for leading the company's primary care and specialty sales teams in the U.S.

Axial Biotherapeutics Inc., of Boston, appointed David Amaral, Alessio Fasano, Daniel Geschwind, Robert L. Hendren, Clara Lajonchere, Sarkis Mazmanian, and Emeran Mayer to its new scientific and clinical advisory board.

Biogen Inc., of Cambridge, Mass., named Amy Chevalier Efantis vice president of government affairs.

Blackthorn Therapeutics Inc., of South San Francisco, appointed Atul R. Mahableshwarkar vice president of clinical development.

Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, added Saiid Zarrabian to its board, and appointed Erich Mohr chairman.

Engene Inc., of Montreal, added Steve Gannon to its board, and appointed him chairman of the audit committee.

Enterome SA, of Paris, added Mary Thistle to its board.

G1 Therapeutics Inc., of Research Triangle Park, N.C., added Andrew Witty to its board.

Gamida Cell Ltd., of Jerusalem, named Ronit Simantov chief medical officer; he will be based in the U.S.

Intec Pharma Ltd., of Jerusalem, named Jeffrey A. Meckler CEO.

Lumicell Inc., of Wellesley, Mass., appointed Kelly Londy CEO, and named W. David Lee president and chief scientific officer.

Nabriva Therapeutics plc, of Dublin, named Francesco Maria Lavino chief commercial officer. He will be based out of the company's U.S. headquarters in King of Prussia, Pa.

Poxel SA, of Lyon, France, added Kumi Sato to its board.

Precision Biosciences Inc., of Durham, N.C., appointed David Thomson chief development officer.

Seres Therapeutics Inc., of Cambridge, Mass., added Willard Dere to its board.

Symic Bio Inc., of San Francisco, named Glenn Prestwich executive vice president of chemistry.

Valneva SE, of Lyon, France, added Sandra E. Poole and Balaji Muralidhar to its board.

Verastem Inc., of Boston, appointed Julie B. Feder chief financial officer.

Viking Therapeutics Inc., of San Diego, added Charles A. Rowland Jr. to its board.